
Roger McIntyre, MD
Professor of Psychiatry and Pharmacology
University of Toronto

What is the Role of Glutamate in Depression?
Friday, February 12, 2027
2:30 PM - 3:30 PM
Using GLP-1s in Psychiatry
Friday, February 12, 2027
3:45 PM - 4:45 PM
Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto. Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022 and 2023 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.
Dr. McIntyre has authored/co-authored more than 1200 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders. Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level. Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada. Additionally, Dr. McIntyre was awarded the Colvin Prize for Outstanding Achievement in Mood Disorders Research from the Brain and Behavior Research Foundation in 2023. Dr. McIntyre has also contributed extensively to clinical practice guidelines. For example, Dr. McIntyre is the lead author the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. In addition, Dr. McIntyre is also the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in Mood Disorders. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders as well as the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders.
Lecture One Summary:
This presentation will examine the evolving understanding of glutamate and its role in the pathophysiology and treatment of major depressive disorder and other mental disorders. The session will trace key developments in glutamate research, from its early discovery to recognition of its importance in neuroplasticity and long-term potentiation. It will also review glutamate dysregulation across psychiatric conditions and provide a clinically focused overview of glutamate-signaling modulators and their emerging role in treating mental disorders and specific domains of psychopathology.
Lecture Two Summary:
This presentation will examine the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in psychiatry, building on their established use in obesity, diabetes, and other chronic diseases. The session will review GLP-1 signaling in the brain and its relationship to processes such as reward, motivation, cognition, and substance use. It will also explore current evidence for the use of GLP-1 RAs in people with mental disorders, including their potential effects on psychopathology and broader health outcomes, and consider whether these agents may have a future role as psychiatric treatments.
Lecture One Goals and Learning Objectives:
-
To review the role of glutamate in neuroplasticity and neurotropism.
-
To summarize glutamate dysregulation across disparate mental disorders.
-
To review glutamate-based signalling modulators and their role in treating mental disorders.
Lecture Two Goals and Learning Objectives:
-
To review the physiology and pathophysiology of GLP-1 signalling in the human brain.
-
To discuss the role of GLP-1 signalling in brain-based behaviour (e.g., reward, motivation).
-
To review a clinical application of GLP-1 RAs in persons with mental disorders.
Disclosures:
Grant/Research Support : CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute
Consultant : Lundbeck, Janssen, Johnson & Johnson, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Biogen, Mitsubishi Tanabe, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eli Lilly, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Bristol Myers Squibb (BMS), Teva, Adhere Tech, GH Research, Autobahn Therapeutics and Atai Life Sciences, Definium, Torrent.
Speakers' Bureau or Honoraria : Lundbeck, Janssen, Johnson & Johnson, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Biogen, Mitsubishi Tanabe, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eli Lilly, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Bristol Myers Squibb (BMS), Teva, Adhere Tech, GH Research, Autobahn Therapeutics and Atai Life Sciences, Definium, Torrent.
.png)